| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1278783L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0178783 |
| P932 | PMC publication ID | 5456383 |
| P698 | PubMed publication ID | 28575121 |
| P50 | author | Vanessa Rosemary Duke Barrs | Q18395232 |
| David Foster | Q64535316 | ||
| P2093 | author name string | Ross Norris | |
| Andrew McLachlan | |||
| Jana Leshinsky | |||
| P2860 | cites work | Elevation of alanine transaminase and gallbladder wall abnormalities as biomarkers of anaphylaxis in canine hypersensitivity patients | Q43217422 |
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Effects of amphotericin B and caspofungin on histamine expression | Q44551295 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis | Q46729762 | ||
| The Split-Apply-Combine Strategy for Data Analysis | Q56910804 | ||
| Effect of histamine, norepinephrine, and nerves on vascular pressures in dog liver | Q68980432 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations | Q80693737 | ||
| Sinonasal and sino-orbital aspergillosis in 23 cats: aetiology, clinicopathological features and treatment outcomes | Q83572807 | ||
| Physiological and haematological findings and clinical observations in a model of acute systemic anaphylaxis in Dirofilaria immitis-sensitised cats | Q83891007 | ||
| Aspergillus felis sp. nov., an emerging agent of invasive aspergillosis in humans, cats, and dogs | Q21133504 | ||
| Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits | Q28369150 | ||
| Genetic relatedness versus biological compatibility between Aspergillus fumigatus and related species | Q30841118 | ||
| Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping | Q31065559 | ||
| Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine | Q31472892 | ||
| Caspofungin: a potential cause of reversible severe thrombocytopenia | Q33364370 | ||
| Invasive aspergillosis due to Neosartorya udagawae | Q33909352 | ||
| Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits | Q33981480 | ||
| Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling | Q33983159 | ||
| Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 | ||
| Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections | Q34481664 | ||
| Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). | Q35138759 | ||
| The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy | Q35185757 | ||
| Fungal β-Glucans and Mammalian Immunity | Q35538040 | ||
| Caspofungin: a review of its use in the treatment of fungal infections | Q36257157 | ||
| Fatal anaphylaxis: postmortem findings and associated comorbid diseases | Q36766696 | ||
| Resistance to echinocandin-class antifungal drugs | Q36849595 | ||
| Update on echinocandin antifungals | Q37118866 | ||
| Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys | Q37121115 | ||
| Human cardiac mast cells in anaphylaxis | Q37762372 | ||
| Anaphylaxis in dogs and cats | Q38121593 | ||
| Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene | Q39116953 | ||
| Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. | Q39652915 | ||
| Responses of the simultaneously-perfused hepatic arterial and portal venous vascular beds of the dog to histamine and 5-hydroxytryptamine | Q40059143 | ||
| Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma | Q40622190 | ||
| Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). | Q42116260 | ||
| Uncommon Neosartorya udagawae fungus as a causative agent of severe corneal infection | Q42773060 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ggplot2 | Q326489 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | e0178783 | |
| P577 | publication date | 2017-06-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats | |
| P478 | volume | 12 |
Search more.